{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:26:04Z","timestamp":1761942364554,"version":"build-2065373602"},"reference-count":93,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2006,4,1]],"date-time":"2006-04-01T00:00:00Z","timestamp":1143849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,4,1]],"date-time":"2006-04-01T00:00:00Z","timestamp":1143849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2006,4]]},"DOI":"10.1053\/j.seminhematol.2005.12.006","type":"journal-article","created":{"date-parts":[[2006,3,19]],"date-time":"2006-03-19T21:09:49Z","timestamp":1142802589000},"page":"S11-S21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"S2","title":["Purine Analogue Combinations for Indolent Lymphomas"],"prefix":"10.1053","volume":"43","author":[{"given":"Nicholas","family":"Di Bella","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2005.12.006_bib1","first-page":"10","article-title":"Cancer statistics, 2005","volume":"55","author":"Jemal","year":"2005","journal-title":"CA Cancer J Clin"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib2","series-title":"Hematology (Am Soc Hematol Educ Program)","first-page":"241","article-title":"Update on epidemiology and therapeutics for non-Hodgkin\u2019s lymphoma","author":"Vose","year":"2002"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib3","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/annonc\/mdh002","article-title":"Indolent lymphoma","volume":"15","author":"Pileri","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib4","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A revised European-American classification of lymphoid neoplasms","volume":"84","author":"Harris","year":"1994","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib5","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1200\/JCO.1999.17.12.3835","article-title":"World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues","volume":"17","author":"Harris","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib6","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJM199304083281409","article-title":"Treatment of non-Hodgkin\u2019s lymphoma","volume":"328","author":"Armitage","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib7","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1093\/jnci\/92.15.1240","article-title":"Cancer surveillance series","volume":"92","author":"Groves","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib8","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin\u2019s lymphoma. The Non-Hodgkin\u2019s Lymphoma Classification Project","volume":"89","year":"1997","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib9","series-title":"Hematology (Am Soc Hematol Educ Program)","first-page":"203","article-title":"Low-grade lymphoma","author":"Winter","year":"2004"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib10","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib11","first-page":"75","article-title":"Natural history of and therapy for the indolent non-Hodgkin\u2019s lymphomas","volume":"20","author":"Horning","year":"1993","journal-title":"Semin Oncol"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJM199807023390104","article-title":"Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin\u2019s lymphoma","volume":"339","author":"Miller","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib13","first-page":"26","article-title":"New chemotherapeutics strategies for the treatment of indolent lymphoid malignancies","volume":"36","author":"Cheson","year":"1999","journal-title":"Semin Hematol"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib14","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1046\/j.1365-2141.1999.01546.x","article-title":"Long-term follow-up of patients with hairy cell leukaemia after treatment with pentostatin or cladribine","volume":"106","author":"Dearden","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib15","first-page":"2981","article-title":"Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin","volume":"96","author":"Flinn","year":"2000","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib16","first-page":"811","article-title":"Rituximab therapy for follicular lymphoma","volume":"88","author":"Cohen","year":"2003","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib17","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1200\/JCO.2002.08.674","article-title":"Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin\u2019s lymphoma","volume":"20","author":"Hainsworth","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib18","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/blood.V81.1.143.143","article-title":"Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2\u2032-deoxyadenosine and 9-beta-D-arabinosyl-2-fluoroadenine","volume":"81","author":"Robertson","year":"1993","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib19","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/1097-0142(19910301)67:5<1291::AID-CNCR2820670503>3.0.CO;2-Y","article-title":"Fludarabine therapy in hairy cell leukemia","volume":"67","author":"Kantarjian","year":"1991","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib20","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/S0140-6736(72)92345-8","article-title":"Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity","volume":"2","author":"Giblett","year":"1972","journal-title":"Lancet"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib21","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1200\/JCO.1995.13.4.974","article-title":"Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia","volume":"13","author":"Grever","year":"1995","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.1053\/j.seminhematol.2005.12.006_bib22","first-page":"109","article-title":"Long term results with 2\u2019deoxycoformycin in hairy cell leukemia","volume":"14","author":"Catovsky","year":"1994","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib23","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1182\/blood.V92.6.1918","article-title":"Long-term follow-up of patients with hairy cell leukemia after cladribine treatment","volume":"92","author":"Saven","year":"1998","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib24","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S1521-6926(02)00089-0","article-title":"Cladribine in the treatment of hairy-cell leukaemia","volume":"16","author":"Goodman","year":"2003","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib25","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1521-6926(03)00002-1","article-title":"Pentostatin in the treatment of hairy-cell leukemia","volume":"16","author":"Grever","year":"2003","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib26","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1200\/JCO.1984.2.12.1336","article-title":"Hairy-cell leukemia","volume":"2","author":"Spiers","year":"1984","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib27","doi-asserted-by":"crossref","first-page":"652","DOI":"10.2165\/00003495-199346040-00006","article-title":"Pentostatin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in lymphoproliferative disorders","volume":"46","author":"Brogden","year":"1993","journal-title":"Drugs"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib28","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1073\/pnas.75.1.472","article-title":"Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency","volume":"75","author":"Cohen","year":"1978","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib29","first-page":"505","article-title":"Non-Hodgkin\u2019s lymphoma","volume":"15","author":"Zinzani","year":"2002","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib30","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1172\/JCI111710","article-title":"Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes","volume":"75","author":"Seto","year":"1985","journal-title":"J Clin Invest"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib31","first-page":"511","article-title":"Preclinical studies on deoxycoformycin and deoxyadenosine as pharmacologic T cell purging tools","volume":"4","author":"Sheridan","year":"1989","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib32","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1182\/blood.V58.5.1043.1043","article-title":"Effect of 2\u2032-deoxycoformycin on erythroid, granulocytic, and T-lymphocyte colony growth","volume":"58","author":"Aye","year":"1981","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib33","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1182\/blood.V83.10.2906.2906","article-title":"2-Chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia","volume":"83","author":"Seymour","year":"1994","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib34","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1182\/blood.V82.6.1695.1695","article-title":"Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment","volume":"82","author":"O\u2019Brien","year":"1993","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib35","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1093\/jnci\/83.22.1678","article-title":"Kinetics of recovery of CD4+ T cells in peripheral blood of deoxycoformycin-treated patients","volume":"83","author":"Steis","year":"1991","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib36","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1200\/JCO.1992.10.1.28","article-title":"Activity of fludarabine in previously treated non-Hodgkin\u2019s low-grade lymphoma","volume":"10","author":"Hochster","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib37","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1200\/JCO.1992.10.5.790","article-title":"Phase II trial of fludarabine phosphate in lymphoma","volume":"10","author":"Redman","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib38","first-page":"28","article-title":"Fludarabine single-agent therapy for relapsed low-grade non-Hodgkin\u2019s lymphomas","volume":"20","author":"Hiddemann","year":"1993","journal-title":"Semin Oncol"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib39","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/00000421-199606000-00012","article-title":"Fludarabine","volume":"19","author":"Falkson","year":"1996","journal-title":"Am J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib40","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/bjc.1991.253","article-title":"Fludarabine phosphate for the treatment of low grade lymphoid malignancy","volume":"64","author":"Whelan","year":"1991","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib41","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1023\/A:1008325110921","article-title":"Fludarabine and cladribine in relapsed\/refractory low-grade non-Hodgkin\u2019s lymphoma","volume":"11","author":"Tondini","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib42","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/oxfordjournals.annonc.a058591","article-title":"Fludarabine","volume":"4","author":"Zinzani","year":"1993","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib43","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1182\/blood.V86.5.1710.bloodjournal8651710","article-title":"2-Chlorodeoxyadenosine activity in patients with untreated, indolent non-Hodgkin\u2019s lymphoma","volume":"86","author":"Saven","year":"1995","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib44","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1200\/JCO.1998.16.3.850","article-title":"Fewer infections, but maintained antitumor activity with lower-dose versus standard-dose cladribine in pretreated low-grade non-Hodgkin\u2019s lymphoma","volume":"16","author":"Betticher","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib45","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1200\/JCO.1994.12.12.2588","article-title":"The role of pentostatin in the treatment of T-cell malignancies","volume":"12","author":"Mercieca","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib46","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1200\/JCO.1991.9.4.565","article-title":"Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease","volume":"9","author":"Cummings","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib47","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/mpo.2950180307","article-title":"2\u2032 Deoxycoformycin (pentostatin) for refractory non-Hodgkin\u2019s lymphoma","volume":"18","author":"Duggan","year":"1990","journal-title":"Med Pediatr Oncol"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib48","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1159\/000227554","article-title":"Pentostatin (2\u2032-deoxycoformycin, dCF) in patients with low-grade (B-T-cell) and intermediate- and high-grade (T-cell) malignant lymphomas","volume":"53","author":"Monfardini","year":"1996","journal-title":"Oncology"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib49","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1200\/JCO.1996.14.4.1262","article-title":"Fludarabine, mitoxantrone, and dexamethasone","volume":"14","author":"McLaughlin","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib50","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1200\/JCO.1994.12.3.575","article-title":"Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma","volume":"12","author":"McLaughlin","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib51","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1023\/A:1008228709612","article-title":"Fludarabine-mitoxantrone combination-containing regimen in recurrent low-grade non-Hodgkin\u2019s lymphoma","volume":"8","author":"Zinzani","year":"1997","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib52","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/1042819031000139765","article-title":"Fludarabine, mitoxantrone and dexamethasone as front-line therapy in elderly patients affected by newly-diagnosed, low-grade non-Hodgkin\u2019s lymphomas with unfavorable prognostic factors","volume":"45","author":"Bordonaro","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib53","doi-asserted-by":"crossref","first-page":"4351","DOI":"10.1182\/blood-2001-12-0269","article-title":"Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma","volume":"100","author":"Tsimberidou","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib54","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/cncr.21151","article-title":"Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen","volume":"104","author":"Tsimberidou","year":"2005","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib55","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1023\/A:1008388824069","article-title":"Efficacy of fludarabine and mitoxantrone (FN) combination regimen in untreated indolent non-Hodgkin\u2019s lymphomas","volume":"11","author":"Zinzani","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib56","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1023\/A:1012551809100","article-title":"Fludarabine and mitoxantrone","volume":"12","author":"Seymour","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib57","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/(SICI)1099-1069(199809)16:3<107::AID-HON630>3.0.CO;2-7","article-title":"Treatment of indolent lymphoma with fludarabine\/mitoxantrone combination","volume":"16","author":"Emmanouilides","year":"1998","journal-title":"Hematol Oncol"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib58","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1200\/JCO.2003.09.047","article-title":"Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma","volume":"21","author":"Velasquez","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib59","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/10428190210177","article-title":"Primary treatment of low-grade non-Hodgkin\u2019s lymphoma with the combination of fludarabine and mitoxantrone","volume":"43","author":"Dimopoulos","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib60","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3109\/10428199909093737","article-title":"Salvage chemotherapy using a combination of fludarabine and cyclophosphamide for refractory or relapsing indolent and aggressive non-Hodgkin\u2019s lymphomas","volume":"33","author":"Lossos","year":"1999","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib61","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1023\/A:1008376728894","article-title":"Fludarabine, cyclophosphamide, and dexamethasone (FluCyD) combination is effective in pretreated low-grade non-Hodgkin\u2019s lymphoma","volume":"10","author":"Lazzarino","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib62","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1200\/JCO.2001.19.5.1414","article-title":"Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia","volume":"19","author":"O\u2019Brien","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib63","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1097\/00001813-200210000-00002","article-title":"The combination of fludarabine and cyclophosphamide results in a high remission rate with moderate toxicity in low-grade non-Hodgkin\u2019s lymphomas","volume":"13","author":"Eucker","year":"2002","journal-title":"Anticancer Drugs"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib64","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1002\/cncr.20234","article-title":"Fludarabine and cyclophosphamide using an attenuated dose schedule is a highly effective regimen for patients with indolent lymphoid malignancies","volume":"100","author":"Tam","year":"2004","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib65","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/ajh.10137","article-title":"Phase II trial of sequential therapy with fludarabine followed by cyclophosphamide, mitoxantrone, vincristine, and prednisone for low-grade follicular lymphomas","volume":"70","author":"Rohatgi","year":"2002","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib66","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1080\/10428190310001623874","article-title":"Fludarabine, cyclophosphamide and mitoxantrone for untreated follicular lymphoma","volume":"45","author":"Santini","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib67","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1080\/10428190310001639489","article-title":"Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin\u2019s lymphoma","volume":"45","author":"Hendry","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib68","first-page":"282","article-title":"Fludarabine in combination with cyclophosphamide or with cyclophosphamide plus mitoxantrone for relapsed or refractory low-grade non-Hodgkin\u2019s lymphoma","volume":"86","author":"Santini","year":"2001","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib69","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1046\/j.1365-2141.2001.03014.x","article-title":"Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone","volume":"114","author":"Di Gaetano","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib70","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1080\/1042819021000046958","article-title":"Combined fludarabine and rituximab for low grade lymphoma and chronic lymphocytic leukemia","volume":"44","author":"Savage","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib71","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1200\/JCO.2005.02.172","article-title":"Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma","volume":"23","author":"Czuczman","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib72","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib73","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1200\/JCO.1996.14.7.2139","article-title":"Cladribine and mitoxantrone dose escalation in indolent non-Hodgkin\u2019s lymphoma","volume":"14","author":"Saven","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib74","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/S0959-8049(02)00143-0","article-title":"Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin\u2019s lymphoma","volume":"38","author":"Rummel","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib75","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3109\/10428199909167397","article-title":"Combination regimen of 2-chlorodeoxyadenosine (cladribine), mitoxantrone and dexamethasone (CMD) in the treatment of refractory and recurrent low grade non-Hodgkin\u2019s lymphoma","volume":"32","author":"Robak","year":"1999","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib76","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1038\/sj.bjc.6690195","article-title":"Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies","volume":"79","author":"Laurencet","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib77","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1034\/j.1600-0609.2001.00303.x","article-title":"Cladribine in combination with mitoxantrone and cyclophosphamide(CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies","volume":"66","author":"Robak","year":"2001","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib78","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1080\/1042819032000159825","article-title":"Rituximab followed by cladribine in the treatment of heavily pretreated patients with indolent lymphoid malignancies","volume":"45","author":"Robak","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib79","first-page":"30","article-title":"Chemotherapy sensitization by rituximab","volume":"27","author":"Wilson","year":"2000","journal-title":"Semin Oncol"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib80","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3816\/CLM.2003.n.026","article-title":"Results of a phase II multicenter trial of pentostatin and rituximab in patients with low grade B-cell non-Hodgkin\u2019s lymphoma","volume":"4","author":"Drapkin","year":"2003","journal-title":"Clin Lymphoma"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib81","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/cncr.20820","article-title":"An open-label pilot study of pentostatin, mitoxantrone, and rituximab in patients with previously untreated, stage III or IV, low-grade non-Hodgkin lymphoma","volume":"103","author":"Di Bella","year":"2005","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib82","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","article-title":"Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly \u00d7 4 schedule","volume":"103","author":"Ghielmini","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib83","first-page":"63","article-title":"Mitoxantrone, prednisone, pentostatin and bleomycin for patients with indolent non-Hodgkin\u2019s lymphoma relapsed or unresponsive to previous treatments. Results of a phase II study conducted by the Gruppo Italiano per lo Studio dei Linfomi (GISL)","volume":"1","author":"Federico","year":"2003","journal-title":"Cancer Ther"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib84","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.beha.2004.08.019","article-title":"What is remission in follicular lymphoma and what is its relevance?","volume":"18","author":"Buckstein","year":"2005","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib85","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1182\/blood.V81.12.3449.3449","article-title":"Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma","volume":"81","author":"Gribben","year":"1993","journal-title":"Blood"},{"issue":"suppl 2","key":"10.1053\/j.seminhematol.2005.12.006_bib86","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/annonc\/5.suppl_2.S73","article-title":"Intensive conventional-dose chemotherapy for stage IV low-grade lymphoma","volume":"5","author":"McLaughlin","year":"1994","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib87","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood.V91.8.2955.2955_2955_2960","article-title":"The clinical significance of molecular response in indolent follicular lymphomas","volume":"91","author":"Lopez-Guillermo","year":"1998","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1053\/j.seminhematol.2005.12.006_bib88","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/annonc\/11.suppl_1.S137","article-title":"Molecular response assessed by PCR is the most important factor predicting failure-free survival in indolent follicular lymphoma","volume":"11","author":"Lopez-Guillermo","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib89","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1182\/blood.V93.9.3081.409a43_3081_3087","article-title":"Correlation of bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma","volume":"93","author":"Lopez-Guillermo","year":"1999","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib90","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1182\/blood.V99.3.856","article-title":"Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma","volume":"99","author":"Rambaldi","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib91","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1200\/JCO.1991.9.9.1527","article-title":"The significance of circulating cells carrying t(14;18) in long remission from follicular lymphoma","volume":"9","author":"Price","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib92","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1200\/JCO.1994.12.8.1541","article-title":"Clinical significance of t(14; 18)-positive cells in the circulation of patients with stage III or IV follicular non-Hodgkin\u2019s lymphoma during first remission","volume":"12","author":"Lambrechts","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2005.12.006_bib93","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1200\/JCO.2005.04.503","article-title":"Improved survival of follicular lymphoma patients in the United States","volume":"23","author":"Swenson","year":"2005","journal-title":"J Clin Oncol"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196305002635?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196305002635?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:17:03Z","timestamp":1758521823000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196305002635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4]]},"references-count":93,"alternative-id":["S0037196305002635"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2005.12.006","relation":{},"ISSN":["0037-1963"],"issn-type":[{"type":"print","value":"0037-1963"}],"subject":[],"published":{"date-parts":[[2006,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Purine Analogue Combinations for Indolent Lymphomas","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2005.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}